Access through your institution

通过您的机构访问

Buy or subscribe

购买或订阅

Efficacious neoadjuvant therapy is an unmet need in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC). Several early-phase clinical trials have investigated the use of immune checkpoint inhibitors (ICIs) in this context, with some promising results. A study in Nature Medicine set out to test whether the efficacy of ICIs could be improved in combination with other therapies.Cretostimogene grenadenorepvec is an oncolytic immunotherapy, which also selectively expresses granulocyte–macrophage colony-stimulating factor (thought to boost cancer control).

对于顺铂不合格的肌肉浸润性膀胱癌（MIBC）患者，有效的新辅助治疗尚未得到满足。一些早期临床试验已经研究了在这种情况下使用免疫检查点抑制剂（ICI），并取得了一些有希望的结果。《自然医学》的一项研究旨在测试ICI的疗效是否可以与其他疗法相结合。Cretostimogene grenadenorepvec是一种溶瘤免疫疗法，它还选择性表达粒细胞-巨噬细胞集落刺激因子（被认为可以促进癌症控制）。

The authors conducted a phase Ib trial of intravesical cretostimogene and nivolumab (an ICI) to test the safety and efficacy of this combination..

作者进行了膀胱内cretostimogene和nivolumab（ICI）的Ib期试验，以测试这种组合的安全性和有效性。。

This is a preview of subscription content, access via your institution

这是订阅内容的预览，可通过您的机构访问

Access options

访问选项

Access through your institution

通过您的机构访问

Access through your institution

通过您的机构访问

Change institution

变革机构

Buy or subscribe

购买或订阅

Access Nature and 54 other Nature Portfolio journals

Access Nature和54种其他Nature投资组合期刊

Get Nature+, our best-value online-access subscription

获取Nature+，我们最具价值的在线访问订阅

24,99 € / 30 days

24,99欧元/30天

cancel any time

随时取消

Learn more

了解更多信息

Subscription info for Chinese customersWe have a dedicated website for our Chinese customers. Please go to naturechina.com to subscribe to this journal.Go to naturechina.com

中国客户的订阅信息我们为中国客户提供了一个专门的网站。请访问naturechina.com订阅本期刊。访问naturechina.com

Buy this article

购买这篇文章

Purchase on SpringerLink

在SpringerLink上购买

Instant access to full article PDF

即时访问全文PDF

Buy now

立即购买

Prices may be subject to local taxes which are calculated during checkout

价格可能需要缴纳结帐时计算的地方税

Additional access options:

其他访问选项：

Log in

登录

Learn about institutional subscriptions

了解机构订阅

Read our FAQs

阅读我们的常见问题

Contact customer support

联系客户支持

ReferencesOriginal articleLi, R. et al. Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial. Nat. Med. https://doi.org/10.1038/s41591-024-03324-9 (2024)Article

参考文献Original articleLi，R。等人。nivolumab在肌肉浸润性膀胱癌中的溶瘤免疫治疗：1b期试验。自然医学。https://doi.org/10.1038/s41591-024-03324-9（2024）条

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Download referencesAuthor informationAuthors and AffiliationsNature Reviews Urology http://www.nature.com/nrurol/Isobel LeakeAuthorsIsobel LeakeView author publicationsYou can also search for this author in

下载参考文献作者信息作者和附属机构泌尿外科评论http://www.nature.com/nrurol/IsobelLeakeAuthorsIsobel LeakeView作者出版物您也可以在

PubMed Google ScholarCorresponding authorCorrespondence to

PubMed谷歌学者通讯社

Isobel Leake.Rights and permissionsReprints and permissionsAbout this articleCite this articleLeake, I. Neoadjuvant therapy in MIBC.

伊莎贝尔·利克。权利和许可打印和许可本文引用本文Leake，I.MIBC中的新辅助治疗。

Nat Rev Urol (2024). https://doi.org/10.1038/s41585-024-00989-2Download citationPublished: 11 December 2024DOI: https://doi.org/10.1038/s41585-024-00989-2Share this articleAnyone you share the following link with will be able to read this content:Get shareable linkSorry, a shareable link is not currently available for this article.Copy to clipboard.

Nat Rev Urol（2024年）。https://doi.org/10.1038/s41585-024-00989-2Download引文发布日期：2024年12月11日OI：https://doi.org/10.1038/s41585-024-00989-2Share本文与您共享以下链接的任何人都可以阅读此内容：获取可共享链接对不起，本文目前没有可共享的链接。复制到剪贴板。

Provided by the Springer Nature SharedIt content-sharing initiative

由Springer Nature SharedIt内容共享计划提供